Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Contestation About Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> Important Lessons From the African Vaccine Manufacturer That Could Not Sell a Single Dose 11/05/2023 Kerry Cullinan Regional vaccine production features in the draft pandemic accord, but there is still a long road before this becomes a reality Aspen Pharmacare invested millions of dollars in scaling up its South African production plant to make COVID-19 vaccines – yet it never sold a single vial. Meanwhile, in a “demoralising blow”, Bangladesh’s government rejected […] Continue reading -> Pharmaceutical CEOs to G7: Protect Intellectual Property Rights and Pathogen Access in WHO Pandemic Accord 14/04/2023 Stefan Anderson CEOs from the world’s largest pharmaceutical companies issued a call to G7 leaders on Friday to oppose the inclusion of intellectual property rights waivers and pathogen benefit sharing in the World Health Organization’s (WHO) pandemic treaty. In meetings with Japanese Prime Minister and chair of next month’s G7 summit Fumio Kishida this week, a delegation […] Continue reading -> Three Years of the COVID-19 Pandemic: ‘A Failure of Multilateralism and Solidarity’ 13/03/2023 Stefan Anderson Three years after the World Health Organization’s (WHO) declaration of the COVID-19 pandemic, the era of hourly headlines updating death and case counts has come to a merciful end. But the virus is still killing around 1,000 people worldwide every day, and it isn’t going anywhere. As of 7 March, WHO has confirmed over 750 […] Continue reading -> U.S. Government Invested $31.9 Billion in mRNA Vaccine Research and Procurement 02/03/2023 Stefan Anderson A new study published in the BMJ has found that the United States invested at least $31.9 billion in public funds directly into the development, production and purchasing of mRNA COVID-19 vaccines through channels ranging from the National Institutes of Health to the Department of Defense. That vast pool of U.S. public funding was indispensable […] Continue reading -> Pathogen Sharing: Pandemic Accord Could Offer Solutions or Further Tangle the Web of Confusion 17/02/2023 Elaine Ruth Fletcher Just 66 days after the SARS-CoV2 genetic sequence was shared by a Chinese scientist online, the first COVID-19 vaccines went into production – in record time for R&D that yielded the first approved vaccines less than a year later. But there are looming concerns that the relatively open models of data and pathogen sharing that […] Continue reading -> Sweeping New Global Biodiversity Deal Sets Out Plan for Sharing Gene Sequences 20/12/2022 Stefan Anderson Along with a pledge to conserve 30% of the world’s biodiversity, the sweeping new deal reached in Montreal on Monday also etches a way forward to create an open-access platform for sharing gene sequences (digital sequence information) as part of new benefit-sharing arrangements. But some observers worry these policy advances still aren’t keeping up with […] Continue reading -> Big Pharma Offers to Reserve Pandemic Products for Poorer Countries in Future – Albeit With Prerequisites 19/07/2022 Kerry Cullinan Major pharmaceutical companies have offered to reserve a “real-time allocation” of vaccines and treatments upfront for “priority populations in lower-income countries” in future pandemics – providing the G7 and G20 also help low-income countries finance and make effective use of the products. Launching its Berlin Declaration on Tuesday, the International Federation of Pharmaceutical Manufacturers and […] Continue reading -> Sanofi Launches Nonprofit Pharmaceuticals Line with Insulin and Cancer Treatments for Low-Income Countries 05/07/2022 John Heilprin French drugmaker Sanofi is the latest pharmaceuticals manufacturer to offer a package of essential medicines at cost to health systems in the world’s most impoverished countries – including much-needed cancer and diabetes treatments. Sanofi on Monday announced the launch of the new nonprofit Impact® brand for dozens of medicines, that is supposed to ease support […] Continue reading -> WHO Projection of 3 Billion Dose Vaccine Shortfall In COVID Booster Scenario – ‘Not Based on Valid Data’ Says Pharma 16/12/2021 Elaine Ruth Fletcher A recent WHO estimate that there could be a 3 billion shortfall in COVID vaccine doses needed to vaccinate the world in the first quarter of 2022 – if high-income countries “aggressively” booster adults with third shots as well as immunizing children is not based on “valid, solid” data, charged pharma leader, Thomas Cueni on […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Important Lessons From the African Vaccine Manufacturer That Could Not Sell a Single Dose 11/05/2023 Kerry Cullinan Regional vaccine production features in the draft pandemic accord, but there is still a long road before this becomes a reality Aspen Pharmacare invested millions of dollars in scaling up its South African production plant to make COVID-19 vaccines – yet it never sold a single vial. Meanwhile, in a “demoralising blow”, Bangladesh’s government rejected […] Continue reading -> Pharmaceutical CEOs to G7: Protect Intellectual Property Rights and Pathogen Access in WHO Pandemic Accord 14/04/2023 Stefan Anderson CEOs from the world’s largest pharmaceutical companies issued a call to G7 leaders on Friday to oppose the inclusion of intellectual property rights waivers and pathogen benefit sharing in the World Health Organization’s (WHO) pandemic treaty. In meetings with Japanese Prime Minister and chair of next month’s G7 summit Fumio Kishida this week, a delegation […] Continue reading -> Three Years of the COVID-19 Pandemic: ‘A Failure of Multilateralism and Solidarity’ 13/03/2023 Stefan Anderson Three years after the World Health Organization’s (WHO) declaration of the COVID-19 pandemic, the era of hourly headlines updating death and case counts has come to a merciful end. But the virus is still killing around 1,000 people worldwide every day, and it isn’t going anywhere. As of 7 March, WHO has confirmed over 750 […] Continue reading -> U.S. Government Invested $31.9 Billion in mRNA Vaccine Research and Procurement 02/03/2023 Stefan Anderson A new study published in the BMJ has found that the United States invested at least $31.9 billion in public funds directly into the development, production and purchasing of mRNA COVID-19 vaccines through channels ranging from the National Institutes of Health to the Department of Defense. That vast pool of U.S. public funding was indispensable […] Continue reading -> Pathogen Sharing: Pandemic Accord Could Offer Solutions or Further Tangle the Web of Confusion 17/02/2023 Elaine Ruth Fletcher Just 66 days after the SARS-CoV2 genetic sequence was shared by a Chinese scientist online, the first COVID-19 vaccines went into production – in record time for R&D that yielded the first approved vaccines less than a year later. But there are looming concerns that the relatively open models of data and pathogen sharing that […] Continue reading -> Sweeping New Global Biodiversity Deal Sets Out Plan for Sharing Gene Sequences 20/12/2022 Stefan Anderson Along with a pledge to conserve 30% of the world’s biodiversity, the sweeping new deal reached in Montreal on Monday also etches a way forward to create an open-access platform for sharing gene sequences (digital sequence information) as part of new benefit-sharing arrangements. But some observers worry these policy advances still aren’t keeping up with […] Continue reading -> Big Pharma Offers to Reserve Pandemic Products for Poorer Countries in Future – Albeit With Prerequisites 19/07/2022 Kerry Cullinan Major pharmaceutical companies have offered to reserve a “real-time allocation” of vaccines and treatments upfront for “priority populations in lower-income countries” in future pandemics – providing the G7 and G20 also help low-income countries finance and make effective use of the products. Launching its Berlin Declaration on Tuesday, the International Federation of Pharmaceutical Manufacturers and […] Continue reading -> Sanofi Launches Nonprofit Pharmaceuticals Line with Insulin and Cancer Treatments for Low-Income Countries 05/07/2022 John Heilprin French drugmaker Sanofi is the latest pharmaceuticals manufacturer to offer a package of essential medicines at cost to health systems in the world’s most impoverished countries – including much-needed cancer and diabetes treatments. Sanofi on Monday announced the launch of the new nonprofit Impact® brand for dozens of medicines, that is supposed to ease support […] Continue reading -> WHO Projection of 3 Billion Dose Vaccine Shortfall In COVID Booster Scenario – ‘Not Based on Valid Data’ Says Pharma 16/12/2021 Elaine Ruth Fletcher A recent WHO estimate that there could be a 3 billion shortfall in COVID vaccine doses needed to vaccinate the world in the first quarter of 2022 – if high-income countries “aggressively” booster adults with third shots as well as immunizing children is not based on “valid, solid” data, charged pharma leader, Thomas Cueni on […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pharmaceutical CEOs to G7: Protect Intellectual Property Rights and Pathogen Access in WHO Pandemic Accord 14/04/2023 Stefan Anderson CEOs from the world’s largest pharmaceutical companies issued a call to G7 leaders on Friday to oppose the inclusion of intellectual property rights waivers and pathogen benefit sharing in the World Health Organization’s (WHO) pandemic treaty. In meetings with Japanese Prime Minister and chair of next month’s G7 summit Fumio Kishida this week, a delegation […] Continue reading -> Three Years of the COVID-19 Pandemic: ‘A Failure of Multilateralism and Solidarity’ 13/03/2023 Stefan Anderson Three years after the World Health Organization’s (WHO) declaration of the COVID-19 pandemic, the era of hourly headlines updating death and case counts has come to a merciful end. But the virus is still killing around 1,000 people worldwide every day, and it isn’t going anywhere. As of 7 March, WHO has confirmed over 750 […] Continue reading -> U.S. Government Invested $31.9 Billion in mRNA Vaccine Research and Procurement 02/03/2023 Stefan Anderson A new study published in the BMJ has found that the United States invested at least $31.9 billion in public funds directly into the development, production and purchasing of mRNA COVID-19 vaccines through channels ranging from the National Institutes of Health to the Department of Defense. That vast pool of U.S. public funding was indispensable […] Continue reading -> Pathogen Sharing: Pandemic Accord Could Offer Solutions or Further Tangle the Web of Confusion 17/02/2023 Elaine Ruth Fletcher Just 66 days after the SARS-CoV2 genetic sequence was shared by a Chinese scientist online, the first COVID-19 vaccines went into production – in record time for R&D that yielded the first approved vaccines less than a year later. But there are looming concerns that the relatively open models of data and pathogen sharing that […] Continue reading -> Sweeping New Global Biodiversity Deal Sets Out Plan for Sharing Gene Sequences 20/12/2022 Stefan Anderson Along with a pledge to conserve 30% of the world’s biodiversity, the sweeping new deal reached in Montreal on Monday also etches a way forward to create an open-access platform for sharing gene sequences (digital sequence information) as part of new benefit-sharing arrangements. But some observers worry these policy advances still aren’t keeping up with […] Continue reading -> Big Pharma Offers to Reserve Pandemic Products for Poorer Countries in Future – Albeit With Prerequisites 19/07/2022 Kerry Cullinan Major pharmaceutical companies have offered to reserve a “real-time allocation” of vaccines and treatments upfront for “priority populations in lower-income countries” in future pandemics – providing the G7 and G20 also help low-income countries finance and make effective use of the products. Launching its Berlin Declaration on Tuesday, the International Federation of Pharmaceutical Manufacturers and […] Continue reading -> Sanofi Launches Nonprofit Pharmaceuticals Line with Insulin and Cancer Treatments for Low-Income Countries 05/07/2022 John Heilprin French drugmaker Sanofi is the latest pharmaceuticals manufacturer to offer a package of essential medicines at cost to health systems in the world’s most impoverished countries – including much-needed cancer and diabetes treatments. Sanofi on Monday announced the launch of the new nonprofit Impact® brand for dozens of medicines, that is supposed to ease support […] Continue reading -> WHO Projection of 3 Billion Dose Vaccine Shortfall In COVID Booster Scenario – ‘Not Based on Valid Data’ Says Pharma 16/12/2021 Elaine Ruth Fletcher A recent WHO estimate that there could be a 3 billion shortfall in COVID vaccine doses needed to vaccinate the world in the first quarter of 2022 – if high-income countries “aggressively” booster adults with third shots as well as immunizing children is not based on “valid, solid” data, charged pharma leader, Thomas Cueni on […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Three Years of the COVID-19 Pandemic: ‘A Failure of Multilateralism and Solidarity’ 13/03/2023 Stefan Anderson Three years after the World Health Organization’s (WHO) declaration of the COVID-19 pandemic, the era of hourly headlines updating death and case counts has come to a merciful end. But the virus is still killing around 1,000 people worldwide every day, and it isn’t going anywhere. As of 7 March, WHO has confirmed over 750 […] Continue reading -> U.S. Government Invested $31.9 Billion in mRNA Vaccine Research and Procurement 02/03/2023 Stefan Anderson A new study published in the BMJ has found that the United States invested at least $31.9 billion in public funds directly into the development, production and purchasing of mRNA COVID-19 vaccines through channels ranging from the National Institutes of Health to the Department of Defense. That vast pool of U.S. public funding was indispensable […] Continue reading -> Pathogen Sharing: Pandemic Accord Could Offer Solutions or Further Tangle the Web of Confusion 17/02/2023 Elaine Ruth Fletcher Just 66 days after the SARS-CoV2 genetic sequence was shared by a Chinese scientist online, the first COVID-19 vaccines went into production – in record time for R&D that yielded the first approved vaccines less than a year later. But there are looming concerns that the relatively open models of data and pathogen sharing that […] Continue reading -> Sweeping New Global Biodiversity Deal Sets Out Plan for Sharing Gene Sequences 20/12/2022 Stefan Anderson Along with a pledge to conserve 30% of the world’s biodiversity, the sweeping new deal reached in Montreal on Monday also etches a way forward to create an open-access platform for sharing gene sequences (digital sequence information) as part of new benefit-sharing arrangements. But some observers worry these policy advances still aren’t keeping up with […] Continue reading -> Big Pharma Offers to Reserve Pandemic Products for Poorer Countries in Future – Albeit With Prerequisites 19/07/2022 Kerry Cullinan Major pharmaceutical companies have offered to reserve a “real-time allocation” of vaccines and treatments upfront for “priority populations in lower-income countries” in future pandemics – providing the G7 and G20 also help low-income countries finance and make effective use of the products. Launching its Berlin Declaration on Tuesday, the International Federation of Pharmaceutical Manufacturers and […] Continue reading -> Sanofi Launches Nonprofit Pharmaceuticals Line with Insulin and Cancer Treatments for Low-Income Countries 05/07/2022 John Heilprin French drugmaker Sanofi is the latest pharmaceuticals manufacturer to offer a package of essential medicines at cost to health systems in the world’s most impoverished countries – including much-needed cancer and diabetes treatments. Sanofi on Monday announced the launch of the new nonprofit Impact® brand for dozens of medicines, that is supposed to ease support […] Continue reading -> WHO Projection of 3 Billion Dose Vaccine Shortfall In COVID Booster Scenario – ‘Not Based on Valid Data’ Says Pharma 16/12/2021 Elaine Ruth Fletcher A recent WHO estimate that there could be a 3 billion shortfall in COVID vaccine doses needed to vaccinate the world in the first quarter of 2022 – if high-income countries “aggressively” booster adults with third shots as well as immunizing children is not based on “valid, solid” data, charged pharma leader, Thomas Cueni on […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
U.S. Government Invested $31.9 Billion in mRNA Vaccine Research and Procurement 02/03/2023 Stefan Anderson A new study published in the BMJ has found that the United States invested at least $31.9 billion in public funds directly into the development, production and purchasing of mRNA COVID-19 vaccines through channels ranging from the National Institutes of Health to the Department of Defense. That vast pool of U.S. public funding was indispensable […] Continue reading -> Pathogen Sharing: Pandemic Accord Could Offer Solutions or Further Tangle the Web of Confusion 17/02/2023 Elaine Ruth Fletcher Just 66 days after the SARS-CoV2 genetic sequence was shared by a Chinese scientist online, the first COVID-19 vaccines went into production – in record time for R&D that yielded the first approved vaccines less than a year later. But there are looming concerns that the relatively open models of data and pathogen sharing that […] Continue reading -> Sweeping New Global Biodiversity Deal Sets Out Plan for Sharing Gene Sequences 20/12/2022 Stefan Anderson Along with a pledge to conserve 30% of the world’s biodiversity, the sweeping new deal reached in Montreal on Monday also etches a way forward to create an open-access platform for sharing gene sequences (digital sequence information) as part of new benefit-sharing arrangements. But some observers worry these policy advances still aren’t keeping up with […] Continue reading -> Big Pharma Offers to Reserve Pandemic Products for Poorer Countries in Future – Albeit With Prerequisites 19/07/2022 Kerry Cullinan Major pharmaceutical companies have offered to reserve a “real-time allocation” of vaccines and treatments upfront for “priority populations in lower-income countries” in future pandemics – providing the G7 and G20 also help low-income countries finance and make effective use of the products. Launching its Berlin Declaration on Tuesday, the International Federation of Pharmaceutical Manufacturers and […] Continue reading -> Sanofi Launches Nonprofit Pharmaceuticals Line with Insulin and Cancer Treatments for Low-Income Countries 05/07/2022 John Heilprin French drugmaker Sanofi is the latest pharmaceuticals manufacturer to offer a package of essential medicines at cost to health systems in the world’s most impoverished countries – including much-needed cancer and diabetes treatments. Sanofi on Monday announced the launch of the new nonprofit Impact® brand for dozens of medicines, that is supposed to ease support […] Continue reading -> WHO Projection of 3 Billion Dose Vaccine Shortfall In COVID Booster Scenario – ‘Not Based on Valid Data’ Says Pharma 16/12/2021 Elaine Ruth Fletcher A recent WHO estimate that there could be a 3 billion shortfall in COVID vaccine doses needed to vaccinate the world in the first quarter of 2022 – if high-income countries “aggressively” booster adults with third shots as well as immunizing children is not based on “valid, solid” data, charged pharma leader, Thomas Cueni on […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pathogen Sharing: Pandemic Accord Could Offer Solutions or Further Tangle the Web of Confusion 17/02/2023 Elaine Ruth Fletcher Just 66 days after the SARS-CoV2 genetic sequence was shared by a Chinese scientist online, the first COVID-19 vaccines went into production – in record time for R&D that yielded the first approved vaccines less than a year later. But there are looming concerns that the relatively open models of data and pathogen sharing that […] Continue reading -> Sweeping New Global Biodiversity Deal Sets Out Plan for Sharing Gene Sequences 20/12/2022 Stefan Anderson Along with a pledge to conserve 30% of the world’s biodiversity, the sweeping new deal reached in Montreal on Monday also etches a way forward to create an open-access platform for sharing gene sequences (digital sequence information) as part of new benefit-sharing arrangements. But some observers worry these policy advances still aren’t keeping up with […] Continue reading -> Big Pharma Offers to Reserve Pandemic Products for Poorer Countries in Future – Albeit With Prerequisites 19/07/2022 Kerry Cullinan Major pharmaceutical companies have offered to reserve a “real-time allocation” of vaccines and treatments upfront for “priority populations in lower-income countries” in future pandemics – providing the G7 and G20 also help low-income countries finance and make effective use of the products. Launching its Berlin Declaration on Tuesday, the International Federation of Pharmaceutical Manufacturers and […] Continue reading -> Sanofi Launches Nonprofit Pharmaceuticals Line with Insulin and Cancer Treatments for Low-Income Countries 05/07/2022 John Heilprin French drugmaker Sanofi is the latest pharmaceuticals manufacturer to offer a package of essential medicines at cost to health systems in the world’s most impoverished countries – including much-needed cancer and diabetes treatments. Sanofi on Monday announced the launch of the new nonprofit Impact® brand for dozens of medicines, that is supposed to ease support […] Continue reading -> WHO Projection of 3 Billion Dose Vaccine Shortfall In COVID Booster Scenario – ‘Not Based on Valid Data’ Says Pharma 16/12/2021 Elaine Ruth Fletcher A recent WHO estimate that there could be a 3 billion shortfall in COVID vaccine doses needed to vaccinate the world in the first quarter of 2022 – if high-income countries “aggressively” booster adults with third shots as well as immunizing children is not based on “valid, solid” data, charged pharma leader, Thomas Cueni on […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Sweeping New Global Biodiversity Deal Sets Out Plan for Sharing Gene Sequences 20/12/2022 Stefan Anderson Along with a pledge to conserve 30% of the world’s biodiversity, the sweeping new deal reached in Montreal on Monday also etches a way forward to create an open-access platform for sharing gene sequences (digital sequence information) as part of new benefit-sharing arrangements. But some observers worry these policy advances still aren’t keeping up with […] Continue reading -> Big Pharma Offers to Reserve Pandemic Products for Poorer Countries in Future – Albeit With Prerequisites 19/07/2022 Kerry Cullinan Major pharmaceutical companies have offered to reserve a “real-time allocation” of vaccines and treatments upfront for “priority populations in lower-income countries” in future pandemics – providing the G7 and G20 also help low-income countries finance and make effective use of the products. Launching its Berlin Declaration on Tuesday, the International Federation of Pharmaceutical Manufacturers and […] Continue reading -> Sanofi Launches Nonprofit Pharmaceuticals Line with Insulin and Cancer Treatments for Low-Income Countries 05/07/2022 John Heilprin French drugmaker Sanofi is the latest pharmaceuticals manufacturer to offer a package of essential medicines at cost to health systems in the world’s most impoverished countries – including much-needed cancer and diabetes treatments. Sanofi on Monday announced the launch of the new nonprofit Impact® brand for dozens of medicines, that is supposed to ease support […] Continue reading -> WHO Projection of 3 Billion Dose Vaccine Shortfall In COVID Booster Scenario – ‘Not Based on Valid Data’ Says Pharma 16/12/2021 Elaine Ruth Fletcher A recent WHO estimate that there could be a 3 billion shortfall in COVID vaccine doses needed to vaccinate the world in the first quarter of 2022 – if high-income countries “aggressively” booster adults with third shots as well as immunizing children is not based on “valid, solid” data, charged pharma leader, Thomas Cueni on […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Big Pharma Offers to Reserve Pandemic Products for Poorer Countries in Future – Albeit With Prerequisites 19/07/2022 Kerry Cullinan Major pharmaceutical companies have offered to reserve a “real-time allocation” of vaccines and treatments upfront for “priority populations in lower-income countries” in future pandemics – providing the G7 and G20 also help low-income countries finance and make effective use of the products. Launching its Berlin Declaration on Tuesday, the International Federation of Pharmaceutical Manufacturers and […] Continue reading -> Sanofi Launches Nonprofit Pharmaceuticals Line with Insulin and Cancer Treatments for Low-Income Countries 05/07/2022 John Heilprin French drugmaker Sanofi is the latest pharmaceuticals manufacturer to offer a package of essential medicines at cost to health systems in the world’s most impoverished countries – including much-needed cancer and diabetes treatments. Sanofi on Monday announced the launch of the new nonprofit Impact® brand for dozens of medicines, that is supposed to ease support […] Continue reading -> WHO Projection of 3 Billion Dose Vaccine Shortfall In COVID Booster Scenario – ‘Not Based on Valid Data’ Says Pharma 16/12/2021 Elaine Ruth Fletcher A recent WHO estimate that there could be a 3 billion shortfall in COVID vaccine doses needed to vaccinate the world in the first quarter of 2022 – if high-income countries “aggressively” booster adults with third shots as well as immunizing children is not based on “valid, solid” data, charged pharma leader, Thomas Cueni on […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Sanofi Launches Nonprofit Pharmaceuticals Line with Insulin and Cancer Treatments for Low-Income Countries 05/07/2022 John Heilprin French drugmaker Sanofi is the latest pharmaceuticals manufacturer to offer a package of essential medicines at cost to health systems in the world’s most impoverished countries – including much-needed cancer and diabetes treatments. Sanofi on Monday announced the launch of the new nonprofit Impact® brand for dozens of medicines, that is supposed to ease support […] Continue reading -> WHO Projection of 3 Billion Dose Vaccine Shortfall In COVID Booster Scenario – ‘Not Based on Valid Data’ Says Pharma 16/12/2021 Elaine Ruth Fletcher A recent WHO estimate that there could be a 3 billion shortfall in COVID vaccine doses needed to vaccinate the world in the first quarter of 2022 – if high-income countries “aggressively” booster adults with third shots as well as immunizing children is not based on “valid, solid” data, charged pharma leader, Thomas Cueni on […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Projection of 3 Billion Dose Vaccine Shortfall In COVID Booster Scenario – ‘Not Based on Valid Data’ Says Pharma 16/12/2021 Elaine Ruth Fletcher A recent WHO estimate that there could be a 3 billion shortfall in COVID vaccine doses needed to vaccinate the world in the first quarter of 2022 – if high-income countries “aggressively” booster adults with third shots as well as immunizing children is not based on “valid, solid” data, charged pharma leader, Thomas Cueni on […] Continue reading -> Posts navigation Older posts